MARKET

ICVX

ICVX

Icosavax, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.01
-1.41
-16.75%
After Hours: 6.85 -0.16 -2.28% 18:30 06/29 EDT
OPEN
6.70
PREV CLOSE
8.42
HIGH
8.49
LOW
5.50
VOLUME
2.25M
TURNOVER
0
52 WEEK HIGH
49.99
52 WEEK LOW
4.000
MARKET CAP
278.49M
P/E (TTM)
-3.2458
1D
5D
1M
3M
1Y
5Y
U.S. Stocks Turn Negative; 2U Shares Spike Higher
U.S. stocks pared gains midway through trading, with all the three major indices turning lower on Wednesday.
Benzinga · 11h ago
Icosavax down 21% following top-line phase 1 data for RSV vaccine candidate
Icosavax (NASDAQ:ICVX) shares have plummeted 21% in after-hours trading following the release of top-line phase 1 data for IVX-121, its Respiratory Syncytial Virus (RSV) vaccine candidate. Results showed that IVX-121 was well-tolerated across all
Seekingalpha · 1d ago
ICVX, MAPS, TCMD and AVAV among after hour movers
Gainers: Tactile Systems Technology (TCMD) +4.9%. Roth CH Acquisition (ROCC) +4.9%. Hertz Global Holdings (HTZ) +4.8%. WM Technology (MAPS) +4.7%. LendingTree (TREE) +4%. Losers: Icosavax (ICVX) -22.0%. AeroVironment (AVAV) -10.1%. Playa Hotels
Seekingalpha · 1d ago
Icosavax Shares Plummet Following Interim Results From Initial-Stage RSV Vaccine Study
Icosavax (NASDAQ: ICVX) announced interim results from its Phase 1/1b clinical trial of IVX-121, respiratory syncytial virus (RSV) F antigen, in young and older adults. The Phase 1/1b clinical trial is designed to evaluate the safety and immunogenicity of ...
Benzinga · 1d ago
Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV
- IVX-121 demonstrated robust immunologic response to RSV, with comparable Geometric Mean Titer (GMT) levels achieved at Day 28 in both young and older adult groups - - IVX-121 was generally well tolerated with no vaccine-related SAEs - - Provides initial ...
GlobeNewswire · 1d ago
Icosavax Reports Interim Trial Results for Respiratory Syncytial Virus Vaccine Candidate; Shares Sink After Hours
MT Newswires · 1d ago
Icosavax's Return on Invested Capital Overview
Icosavax (NASDAQ:ICVX) brought in sales totaling $582.00 thousand during Q1 according to data provided by Benzinga Pro. However, earnings decreased 29.43%, resulting in a loss of $23.53 million.
Benzinga · 06/22 13:57
Icosavax to Participate in the Jefferies Healthcare Conference
SEATTLE, June 01, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle platform technology to develop combination vaccines against infectious diseases, with an initial focus on li...
GlobeNewswire · 06/01 20:05
More
No Data
Learn about the latest financial forecast of ICVX. Analyze the recent business situations of Icosavax, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
25.00%Buy
25.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ICVX stock price target is 25.50 with a high estimate of 41.00 and a low estimate of 10.00.
High41.00
Average25.50
Low10.00
Current 7.01
EPS
Actual
Estimate
-2.29-1.72-1.14-0.57
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 65
Institutional Holdings: 31.73M
% Owned: 79.88%
Shares Outstanding: 39.73M
TypeInstitutionsShares
Increased
30
3.09M
New
18
825.43K
Decreased
10
1.92M
Sold Out
5
1.82M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.71%
Pharmaceuticals & Medical Research
+0.64%
Key Executives
Non-Executive Chairman/Independent Director
Mark McDade
President/Chief Executive Officer/Director
Adam Simpson
Chief Financial Officer
Thomas Russo
Senior Vice President
Charles Richardson
Chief Scientific Officer
Douglas Holtzman
General Counsel/Secretary
Elizabeth Bekiroglu
Other
Cassia Cearley
Other
Niranjan Kanesa-Thasan
Independent Director
Peter Kolchinsky
Independent Director
Heidi Kunz
Independent Director
John Shiver
Independent Director
Ann Veneman
No Data
No Data
About ICVX
Icosavax, Inc. is a biopharmaceutical company. The Company uses its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with a focus on respiratory diseases. Its VLP platform technology is designed to enable the multivalent, particle-based display of complex viral antigens. The Company's pipeline includes vaccine candidates targeting viral causes of pneumonia. Its vaccine candidate IVX-A12 is a bivalent candidate or a mixture of two different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus (RSV), and IVX-241, a vaccine candidate designed to target human metapneumovirus. It is conducting a Phase I/II clinical trial of its coronavirus disease 2019 (COVID-19) candidate IVX-411 in Australia. It is conducting further analysis of the data and its IVX-411 vaccine candidate, including an investigation into the manufacture, shipment and vaccine administration in Phase I/II clinical trial.

Webull offers kinds of Icosavax Inc stock information, including NASDAQ:ICVX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICVX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICVX stock methods without spending real money on the virtual paper trading platform.